Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Iovance Biotherapeutics (IOVA) Asset Writedowns and Impairment (2024 - 2025)

Iovance Biotherapeutics has reported Asset Writedowns and Impairment over the past 5 years, most recently at $3.7 million for Q4 2025.

Quarterly results put Asset Writedowns and Impairment at $3.7 million for Q4 2025, down 49.67% from a year ago — trailing twelve months through Dec 2025 was $12.5 million (up 69.39% YoY), and the annual figure for FY2025 was $13.4 million, up 82.24%.
Asset Writedowns and Impairment for Q4 2025 was $3.7 million at Iovance Biotherapeutics, up from $1.4 million in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for IOVA hit a ceiling of $7.4 million in Q4 2024 and a floor of $1.4 million in Q3 2025.